Tirzepatid
Tirzepatide · GIP/GLP-1 receptor agonist
Tirzepatide activates GIP and GLP-1 receptors. Approved products have their own indications and administration requirements.
Approvals
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
Tirzepatide is a defined GIP/GLP-1 receptor agonist peptide. Mounjaro and Zepbound are described in their product and regional contexts.
- Human research
- Strong
- Replication
- Multiple independent groups
- Clinical endpoints
- Symptom- or function-related
- Safety
- Characterized by prescribing information or extensive studies
- Approval
- EU · ApprovedUS · Approved
The dimensions are presented separately and are not combined into an overall score.
Research gaps
- ·Product-specific findings are not a general recommendation.
Mechanism
Affects appetite and glucose-dependent insulin secretion; delays gastric emptying.
- Zepbound: US prescribing information (DailyMed)Prescribing information2026
U.S. National Library of Medicine (DailyMed)
Accessed:
- Mounjaro: EU product information (EMA)Prescribing information2026
European Medicines Agency
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Common gastrointestinal symptoms; warnings cover pancreatitis, gallbladder disease and dehydration.
Contraindications and warnings
- ·US label: MTC history, MEN2 or serious hypersensitivity. Discontinue in pregnancy; consider severe gastroparesis warnings.
Interactions
- ·Insulin/sulfonylureas: hypoglycemia risk. Oral contraception: additional measures after initiation and escalation per label.
Research gaps
- ·Product-specific findings are not a general recommendation.
- Zepbound: US prescribing information (DailyMed)Prescribing information2026
U.S. National Library of Medicine (DailyMed)
Accessed:
- Mounjaro: EU product information (EMA)Prescribing information2026
European Medicines Agency
Accessed:
Sources
Sources checked: · Version 3
- Zepbound: US prescribing information (DailyMed)Prescribing information2026
U.S. National Library of Medicine (DailyMed)
Accessed:
- Mounjaro: EU product information (EMA)Prescribing information2026
European Medicines Agency
Accessed: